Optimal Duration Of Androgen Deprivation Therapy Following Radiation Therapy In Intermediate- Or High-risk Nonmetastatic Prostate Cancer: A Systematic Review And Metaanalysis.

dc.creatorLeal, Frederico
dc.creatorFigueiredo, Maximiliano Augusto Novis de
dc.creatorSasse, Andre Deeke
dc.date
dc.date2016-05-23T19:41:36Z
dc.date2016-05-23T19:41:36Z
dc.date.accessioned2018-03-29T01:29:06Z
dc.date.available2018-03-29T01:29:06Z
dc.identifierInternational Braz J Urol : Official Journal Of The Brazilian Society Of Urology. v. 41, n. 3, p. 425-434
dc.identifier1677-6119
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/?term=26200535
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/235584
dc.identifier26200535
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1303827
dc.descriptionTo investigate current evidence on the optimal duration of adjuvant hormone deprivation for prostate cancer treated with radiation therapy with curative intent. A systematic search was performed in electronic databases. Data from randomized trials comparing different durations of hormone blockade was collected for pooled analysis. Overall survival, disease-free survival, disease-specific survival and toxicity were the outcomes of interest. Meta-analyses were performed using random-effects model. Six studies met the eligibility criteria. For overall survival, the pooled data from the studies demonstrated a statistically significant benefit for longer hormone deprivation (Hazard Ratio 0.84; 95% CI 0.74 - 0.96). A statistically significant benefit was also found for disease-free survival (Hazard Ratio 0.74; 95% CI 0.62 - 0.89), and disease-specific survival (Hazard Ratio 0.73; 95% CI 0.62 - 0.85). Studies with longer blockade duration arm demonstrated greater benefit. Toxicity was low, with no increase in cardiovascular events. Longer duration of androgen deprivation combined to radiotherapy prolongs OS, DFS and DSS in patients with intermediate and high-risk non-metastatic prostate cancer. However, this evidence is based on trials using older radiation techniques, and further research of combination of androgen deprivation and new RT technologies may be warranted.
dc.description41
dc.description425-434
dc.languageeng
dc.relationInternational Braz J Urol : Official Journal Of The Brazilian Society Of Urology
dc.relationInt Braz J Urol
dc.rightsfechado
dc.sourcePubMed
dc.subjectAndrogen Antagonists
dc.subjectChemotherapy, Adjuvant
dc.subjectDisease-free Survival
dc.subjectHumans
dc.subjectMale
dc.subjectNeoadjuvant Therapy
dc.subjectPrognosis
dc.subjectProstatic Neoplasms
dc.subjectRandomized Controlled Trials As Topic
dc.subjectReproducibility Of Results
dc.subjectRisk Assessment
dc.subjectTime Factors
dc.titleOptimal Duration Of Androgen Deprivation Therapy Following Radiation Therapy In Intermediate- Or High-risk Nonmetastatic Prostate Cancer: A Systematic Review And Metaanalysis.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución